

Content

Content.....	III
List of figures.....	VI
List of tables.....	VI
List of abbreviations.....	VII
Part I. Introduction	1
1 European Regulation of medical devices.....	3
2 National Provisions in Germany	5
2.1 German Social Security Code (SGB)	5
2.1.1 Relevant rules.....	6
2.1.2 No regulation of cost effectiveness of medical devices.....	7
2.2 German medical devices law (MPG)	7
2.3 IQWiG guidance	8
3 National provisions in England / Wales	9
3.1 Precedent in English law	9
3.2 Statutory law (Acts of Parliament).....	9
3.3 Secondary legislation	11
3.3.1 Implications for clinical practice.....	13
3.3.2 Funding technology appraisal guidance.....	14
3.4 Quasi-law	15
3.5 Summary.....	16
4 Terminology	19
4.1 Definition of medical devices	19
4.2 Medicinal products and medical devices.....	19
5 Structure of both health care systems.....	21
5.1 National health system in England	21
5.1.1 Structure.....	21
5.1.2 Primary Care	21

5.1.3	Secondary Care	22
5.2	National health system in Germany	23
5.3	Major Players.....	23
5.3.1	NHS authorities and trusts.....	24
5.3.2	National Institute for Health and Clinical Excellence (NICE)	27
5.3.3	Federal Joint Committee (G-BA)	31
5.3.4	Institut für Qualitätssicherung und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	32
6	New developments: White Paper 2010	35
	Part II. Economic valuation of medical devices	37
7	What makes medical devices special	39
8	NICE's technology appraisal.....	41
8.1	Appraisal process	42
8.2	Economical method: Cost Utility Analysis	43
8.2.1	QALY.....	43
8.2.2	NICE's cost effectiveness threshold	45
8.3	Appeals	48
9	Evaluation pathway programme for medical devices	49
9.1	Selecting medical technologies.....	49
9.2	Routing of selected technologies for evaluation	50
9.3	Developing medical technologies guidance	51
9.3.1	Scope.....	52
9.3.2	The manufacturer's submission.....	55
9.3.3	Contributions from expert advisers.....	56
9.3.4	Patient advisers	57
9.4	Assessment	57
9.4.1	Evidence synthesis.....	57
9.4.2	Indirect and intermediate clinical and system outcomes	58
9.4.3	Modelling of cost consequences	58
9.5	Evaluation of the evidence and decision-making	60
9.6	Case study.....	61
9.6.1	Why developing guidance on SeQuant® Please.....	61
9.6.2	Description of the technology and regulatory status	62

9.6.3	Assessment report	63
9.7	Result	69
10	IQWiG's efficiency frontier.....	71
10.1	Concept	71
10.2	Designing the efficiency frontier	73
10.3	Rationale and recommendations.....	74
10.4	Using efficiency frontier concept for medical devices	75
10.4.1	Two steps approach	76
10.4.2	No experience with the efficiency frontier.....	76
10.4.3	Threshold	77
10.4.4	Exclusion of QUALYs	77
10.4.5	Perspective of Costs.....	78
10.4.6	Timeframe of cost estimation.....	79
Part III.	Legal Analysis	81
11	The fairness problem: Refusal of treatment.....	83
11.1	National provisions	83
11.2	International/European provisions	86
12	Technology appraisal: the Eisai case	89
12.1	Facts	89
12.2	Procedural Fairness	90
12.3	Level of disclosure	91
12.4	Confidentiality	92
Part IV.	Summary.....	95
Bibliography	97